International agreement statements for monitoring disease activity in Crohn’s disease patients: The results of the IBD AHEAD 2011 project

Česká verzia

Authors: M. Lukáš
Authors place of work: Ústav klinické biochemie a laboratorní diagnostiky VFN a 1. LF UK v Praze ; Klinické a výzkumné centrum pro střevní záněty, ISCARE Lighthouse a 1. LF UK v Praze
Published in the journal: Gastroent Hepatol 2012; 66(2): 136-141
Category: IBD: Review Article

Summary

IBD AHEAD 2011 is an international project involving 36 countries which aimed to obtain agreement statements for monitoring disease activity in patients with Crohn’s disease. Four clinical options were determined: baseline assessment; monitoring in symptomatic patients, monitoring in asymptomatic patients; monitoring in post-operative patients. The international agreement statements showed that a symptom’s evaluation is not enough to achieve a precise disease activity assessment. Besides standard laboratory investigations, (CRP) faecal markers (calprotectin) are used. Ileocolonoscopy and magnetic resonance enterography represent “the golden standard” imaging techniques. Ileocolonoscopy is a crucial method for monitoring patients after surgery.

Key words:
Crohn’s disease – patient monitoring – laboratory markers – endoscopy – imaging methods

Zdroje

1. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn´s disease: a prospective multicentre study. Groupe d´Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989; 30(7): 983–989.

2. Daperno M, D´Haens G, Van Assche G et al. Development and validation of a new, simplified endoscopic activity score for Crohn´s disease: the SES-CD. Gastrointest Endosc 2004; 60(4): 505–512.

3. Rutgeerts P, Geboes K, Vantrappen G et al. Predictability of the postoperative course of Crohn´s disease. Gastroenterology 1990; 99(4): 956–963.

4. Lukáš M, Bortlík M. Český konsenzus k projektu IBD Ahead 2011. Biol Lecba 2011; 4(2): 52–57.

Autor deklaruje, že v souvislosti s předmětem studie nemá žádné komerční zájmy.

The author declares he has no potential conflicts of interest concerning drugs, products, or services used in the study.